Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 2 058 DKK 2.69% Market Closed
Market Cap: 132B DKK
Section:
 

Relative Value

The Relative Value of one GMAB stock under the Base Case scenario is 521.19 DKK. Compared to the current market price of 2 058 DKK, Genmab A/S is Overvalued by 75%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GMAB Relative Value
Base Case
521.19 DKK
Overvaluation 75%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

35.4
P/S
P/S
Price to Sales
35.4
vs History
77
vs Industry
66
Median 3Y
48.9
Median 5Y
79.7
Industry
7.8
Forward
34
More Details
85.5
P/E
P/E
Price to Earnings
85.5
vs History
84
vs Industry
10
Median 3Y
159.7
Median 5Y
220.5
Industry
24.1
Forward
109.6
More Details
99.4
P/OCF
P/OCF
Price to OCF
99.4
vs History
82
vs Industry
13
Median 3Y
123
Median 5Y
164.8
Industry
21.8
More Details
106.7
P/FCFE
P/FCFE
Price to FCFE
106.7
vs History
80
vs Industry
11
Median 3Y
131.7
Median 5Y
175.8
Industry
23.8
More Details
22
P/B
P/B
Price to Book Value
22
vs History
77
vs Industry
38
Median 3Y
26.8
Median 5Y
42.3
Industry
3.3
More Details
34.4
EV/S
EV/S
Enterprise Value to Sales
34.4
vs History
77
vs Industry
61
Median 3Y
47.3
Median 5Y
78
Industry
8
Forward
33.1
More Details
36.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
36.5
vs History
41
vs Industry
64
Median 3Y
43.9
Median 5Y
32.5
Industry
10.3
More Details
89
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
89
vs History
82
vs Industry
12
Median 3Y
146.1
Median 5Y
157.6
Industry
6.3
Forward
87.3
More Details
93.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
93.5
vs History
82
vs Industry
10
Median 3Y
147.9
Median 5Y
164.2
Industry
6.7
Forward
94.5
More Details
96.8
EV/OCF
EV/OCF
Enterprise Value to OCF
96.8
vs History
82
vs Industry
14
Median 3Y
119.5
Median 5Y
161.1
Industry
7.9
More Details
102.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
102.5
vs History
80
vs Industry
10
Median 3Y
125.6
Median 5Y
169.2
Industry
6.3
More Details
34.2
EV/IC
EV/IC
Enterprise Value to IC
34.2
vs History
74
vs Industry
42
Median 3Y
114
Median 5Y
163.1
Industry
5.5
More Details

Multiples Across Competitors

GMAB Competitors Multiples
Genmab A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Genmab A/S
CSE:GMAB
126.7B DKK 35.4 85.5 89 93.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 837 682.7 -160 825.5 -195 293.4 -193 064.9
US
Abbvie Inc
NYSE:ABBV
400.9B USD 6.7 170.7 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 9.9 31.5 23.1 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 082 -531.3 -578.5 -563.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.8 19.1
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.6 18.7 12.6 15.7
NL
argenx SE
XBRU:ARGX
45B EUR 14.6 34.4 59.4 61.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.8 159.1 192.9
P/S Multiple
Revenue Growth P/S to Growth
DK
Genmab A/S
CSE:GMAB
Average P/S: 3 076 351.6
35.4
16%
2.2
FR
Pharnext SCA
OTC:PNEXF
33 837 682.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 082
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.6
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
P/E Multiple
Earnings Growth PEG
DK
Genmab A/S
CSE:GMAB
Average P/E: 179.3
85.5
9%
9.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 825.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
9%
2
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
34.4
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBITDA: 45.3
89
22%
4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 293.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
59.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBIT: 51.2
93.5
20%
4.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
61.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.9
N/A N/A

See Also

Summary
GMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
GMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GMAB stock valuation using valuation multiples.
Wall Street Estimates
GMAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.